Related Experiment Video
Updated: Jun 11, 2026
09:37
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
CYP1A1 gene polymorphisms as a risk factor for pterygium.
Chi-Hsien Young1, Yu-Lun Lo, Yi-Yu Tsai
1Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Molecular Vision
|July 3, 2010
Summary
Genetic variations in cytochrome P4501A1 (CYP1A1) are linked to an increased risk of pterygium. Glutathione S-transferase M1 (GSTM1) polymorphisms showed no significant association with pterygium development.
Area of Science:
- Ophthalmology
- Genetics
- Environmental Health
Background:
- Polycyclic aromatic hydrocarbons (PAHs) are environmental pollutants metabolized by enzymes like cytochrome P4501A1 (CYP1A1) and glutathione S-transferase M1 (GSTM1).
- Benzo(a)pyrene (BaP) metabolites, such as BPDE-N2-dG adducts, can cause DNA damage and mutations, potentially contributing to diseases.
- Previous research linked CYP1A1 gene polymorphisms to BPDE-like DNA adduct levels in pterygium.
Purpose of the Study:
- To investigate the association between genetic polymorphisms of CYP1A1 and GSTM1 and the risk of developing pterygium.
- To determine if CYP1A1 and GSTM1 genetic variations are predictive markers for pterygium susceptibility.
Main Methods:
- Genotyping of CYP1A1 and GSTM1 was performed using DNA extracted from blood samples of 205 pterygium patients and 206 controls.
- Restriction fragment length polymorphism and polymerase chain reaction techniques were employed for mutation and genotype determination.
Main Results:
- A significant difference in CYP1A1 genotype distribution was observed between pterygium cases and controls (p=0.0161).
- CYP1A1 m2/m2 polymorphism showed a significantly increased odds ratio (1.647, p=0.006) for pterygium compared to the wild-type.
- No significant association was found between GSTM1 polymorphisms and pterygium risk (p=1.000).
Conclusions:
- CYP1A1 genetic polymorphism is significantly correlated with pterygium.
- CYP1A1 variations may serve as a potential biomarker for predicting pterygium susceptibility.
- GSTM1 polymorphisms do not appear to influence pterygium risk in this population.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...